Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Diabetes Treatment
- Cancer
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279366
US Application Serial No. 09/546,733
Biological Materials shall mean the vascular endothelial growth factor-2 gene referred to as “VEGF-2†and proprietary naked plasmid DNA encoding for VEGF-2, including the plasmid DNA sometimes referred to as “phVEGF-2†or “pVGI.1(VEGF2)â€, together with any Progeny, Derivatives and Modifications therefrom.
Initial Product shall mean a product for the treatment of peripheral diabetic neuropathy that incorporates Biological Materials.
Licensed Product shall mean any product or method in the Field of Use covered by one or more Valid Claims.
Intellectual Property shall mean all intellectual property rights, including (i) United States and other national patents and patent applications, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations, requests for continued examination, supplemental registrations or extensions thereof, (ii) trademarks, whether registered or unregistered and applications for registration thereof, (iii) copyrights, whether registered or unregistered and applications for registration thereof, and (iv) trade secrets, know-how, technology, proprietary information and data, including formulae, procedures, plans, methods, processes, specifications, models, protocols, techniques and experimentation, and design, testing and manufacturing data, and products, compositions, and procedures.
Peripheral neuropathy refers to the conditions that result when nerves that carry messages to and from the brain and spinal cord from and to the rest of the body are damaged or diseased. The peripheral nerves make up an intricate network that connects the brain and spinal cord to the muscles, skin, and internal organs.
IPSCIO Record ID: 289232
Licensee hereby grants to Licensor an exclusive license with sublicensing rights under Licensee Technology, to research, develop, formulate, make, have made, use, sell, offer for sale, import and export Products in the Field of Use in the Licensor Territory.
Licensed Patent Rights shall mean the patents and patent applications listed and any Patent Rights based thereon.
US Patent #5,594,100 – Epitope for prevention of type I diabetes
US Application #09/255,668 – Methods for treating diabetes using peptide analogs
Licensed Technology shall mean any technology, trade secrets, know-how and other intellectual property (other than Trademarks) directed to products, processes, formulations and/or methods and any biological materials owned or Controlled on the Effective Date or to be owned or Controlled thereafter by Licensor or its Affiliates which are necessary to research, develop, formulate, make, use or sell NBI-6024 and shall include the Licensed Patent Rights, Licensor Data and Manufacturing Technology.
Licensor Data shall mean the pre-clinical and clinical data collected by Licensor or its Affiliates in support of the CTX.
CTX shall mean the NBI-6024 CTX filed by Licensor with the Medicines Control Agency in the United Kingdom on December 15, 1998.
NBI-6024 shall mean altered peptide ligand as defined by the amino acid sequence set forth. NBI-6024 is the acetate salt of a synthetic peptide of 15 naturally occurring amino acids based on a sequence derived from the B chain of human insulin. All GLP safety studies and proposed clinical studies will use fully characterized GMP material.
Manufacturing Technology shall mean technology and know-how owned or Controlled by Licensor or its Affiliates which relate to the manufacture of NBI-6024 as set forth in the CTX and any other technology, know-how or standard operating procedures implemented by Licensor or its Affiliates which are actually being used by Licensor or its Affiliates to manufacture Products during the term of this Agreement.
Taisho Technology shall mean any technology, trade secrets, know-how and other intellectual property (other than Trademarks) directed to products, processes, formulations and/or methods and any biological materials owned or Controlled on the Effective Date or to be owned or Controlled thereafter by Taisho or its Affiliates which are necessary to research, develop, formulate, make, useor sell NBI-6024.
Patent Right shall mean patent applications, patents issuing thereon and any extensions or restorations by existing or future extension or restoration mechanisms including Supplementary Protection Certificates or the equivalent thereof, renewals, continuations, continuations-in-part, divisions, patents-of-addition, and/or reissues of any patent, which have not lapsed, been canceled or become abandoned and have not been declared invalid or unenforceable by an unreversed and unappealable decision or judgement of a court or other appropriate body of competent jurisdiction.
IPSCIO Record ID: 351975
Peripheral neuropathy is nerve damage caused by chronically high blood sugar and diabetes. It leads to numbness, loss of sensation, and sometimes pain in your feet, legs, or hands. It is the most common complication of diabetes.
IPSCIO Record ID: 362445
Licensor retains the right to use the Patents and consent to the use of the Patents by academic and research institutions for non-commercial purposes, free of charge. Licensor is further allowed to use the Patents for non-commercial collaborations with commercially oriented third parties. In case of any commercialization by said third party, this party has to negotiate an agreement with Licensor/Licensee or the Licensee directly, as the case may be. For purpose of clarification, non-commercial purposes does not include human clinical trials. Licensee gets a free, non-exclusive license on Blocking Inventions held by Licensor if this is required to commercialize the Patents and only to the extent that no third party rights existing as of the Effective Date are in conflict with such a non-exclusive license.
Licensee is obliged to use diligent and reasonable efforts to develop and commercially exploit the Patents in connection with at least one Licensed Product to the maximum extent worldwide and throughout the Territory.
Licensee has the right to grant Sub-licenses within the scope of this Agreement.
Patent(s) shall mean (1) patent (application) [US 61/180,024 and US 61/322,878 (Licensor internal reference number T-08-084), any members of the patent family claiming priority of these original patent applications, including any patent application or granted patent, whether domestic or foreign, including all provisionals, and all divisionals, continuations, continuations-in-part, reissues, reexaminations, renewals, extensions, and supplementary protection certificates of any such patents and patent applications, and (ii) any patent issuing therefrom.
Patent rights related to the use of anti-miR therapeutics targeting miR-103/107 for the treatment of metabolic disorders, including type 2 diabetes.
IPSCIO Record ID: 367328
The license granted under this Agreement is granted only to the Licensee and not to any Affiliated Companies. The Licensee will not cross-license the Technology or any Improvements without the prior written consent of University, which consent will not be unreasonably withheld.
The Licensee will not grant sublicenses of the Technology, University Improvements or any Joint Improvements to Affiliated Companies or other third parties without the prior written consent of University which consent will not be unreasonably withheld.
Technology means the Patents and all knowledge, know-how and/or technique or techniques invented, developed and/or acquired, before the Effective Date by University or the Licensee relating to, and including, the technology and materials described, as amended from time to time, including, without limitation all related research, data, specifications, instructions, manuals, papers or other related materials of any nature at all, whether written or otherwise, and University’s Confidential Information.
U.S. Provisional filed
April 18, 2003, Serial No.
60/463,952 Hsp27 Antisense to Treat Prostate and other Solid Tumours.
Patents mean collectively the rights in and to any and all inventions which are disclosed in the U.S., Canadian and foreign patents and patent applications identified and all
(i) counterparts, continuations, divisionals, continuations-in-part, continuing prosecution applications, and requests for continued examinations, extensions, term restorations, renewals, reissues, re-examinations, or substitutions thereof;
(ii) corresponding international patent applications;
(iii) corresponding foreign patent applications, including supplementary protection certificates and other administrative protections; and
(iv) international and foreign counterpart patents resulting therefrom, all of which will be deemed added, from time to time.
U.S. Provisional filed October 2, 2002, Serial
No. 60/415,859 Hsp27 Antisense to Treat Prostate and other Solid Tumours.
Product(s) means goods or services manufactured or provided in connection with the use of all or some of the Technology and/or any Improvements.
IPSCIO Record ID: 308734
Patent Application US Serial # 07/551,270 -Novel Receptor-Type Phosphotyrosinc Phosi1hatases
Patent Application US Serial # 07/654,188 – Novel Rcccptor-lype Phospholyrosine PhosEltatases
Research Technology shall mean all University Patents and University Know-How.
Licensee Product shall mean any product for the diagnosis, treatment or prevention of human disease which contains or comprises
(i) any Receptor (as hereinafter defined); and/or (ii) any substance which activates or prevents activation or otherwise modulates activation of a Receptor; and/or (iii) any substance which induces, prevents or otherwise modulates intracellular activity of either the activated or resting Receptor and/or (iv) any substance otherwise physically interacts with a Receptor and/or (v) DNA or RNA encoding any of said substances, including probes, vectors or cells modified to contain such DNA or RNA; provided that an Investigational New Drug (IND) application is filed for such Licensee Product within 4 years from the end of the Research Period. Licensee Product shall not include any product that is licensed by Licensee from a third party other than MPG, provided that such product does not act by activating, preventing activation, or otherwise modulating a Validated Target.
MPG shall mean Max-Planck-1 Institut fur Biochemie, Abteilung Molekularbiologie (Director Prof. Dr. Axel Ullrich), located in Am Klopferspitz 18a, W-8003 Martinsreid, an institute of the Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., located in Residenzstrasse 1a, W-8000 Munchen 2, or any scientist affiliated with Max-Planck-1 Institut fur Biochemie, and/or Garching Intrumente Gesellschaft zur industriellen Nutzung von Forschungsergebnissen m.b.h. located in Koniginstrabe 19, W-8000 Munchen 22.
University Patents shall mean Universitys share in all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor (x) which claim Pre-Existing Inventions and which are identified on Appendix I hereto; or (y) which claim inventions that are made, in whole or in part, by students or employees of University (including the University Scientist) during the term and in the course of the University Research Project (as hereinafter defined). For the avoidance of doubt, University Patents shall include any such inventions that are made during the term and in the course of the University Research Project, whether funded by Licensee or by United States government agencies under Section 4( c) hereof.
University Know-How shall mean the Pre-Existing Inventions and any information and materials (including, but not limited to, pharmaceutical, chemical, biological and biochemical products, information, trade secrets, know-how, technical and non-technical data, materials, methods and processes and any drawings, plans, diagrams, specifications and/or other documents containing such information) discovered, developed or acquired by or on behalf of students or employees of University (including The University Scientist) during the term and in the course of the University Research Project (as hereinafter defined). For the avoidance of doubt, University Know-How shall include any of the foregoing that are developed during the term and in the course of the University Research Project whether funded by Licensee or by United States government agencies wider Section 4( c) hereof.
Receptor shall mean
(i) receptor tyrosine kinases, intracellular tyrosine kinases, or receptors that directly or indirectly activate non-receptor tyrosine kinases; and/or (ii) receptor serine/threonine kinases, intracellular serine/threonine kinases, or receptors that directly or indirectly activate serine/threonine kinases and/or (iii) receptor tyrosine phosphatases, intracellular tyrosine phosphatases, or receptors that directly or indirectly activate tyrosine phosphatases; and/or (iv) molecules that regulate the signaling of the above receptors.
The Licensees objective is to discover and develop new classes of small molecule drugs which interact in a specific manner with different members of the tyrosine kinase, serine-threonine kinase and tyrosine phosphatase families of signal transduction pathways. These pathways are involved in a number of human diseases including cancer and diabetes as well as disorders of the bodys immune defenses and neurological systems.
